Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial (MULTI-EXA)
Acute Exacerbation of COPD

About this trial
This is an interventional treatment trial for Acute Exacerbation of COPD focused on measuring AECOPD, respiratory multiplex PCR, Appearance of sputum, Procalcitonin, Antibiotics saving, Diagnosis, Treatment
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years old
- COPD (according to GOLD 2020), whatever the stage (I-IV)
- Acute exacerbation (according to GOLD 2020: acute worsening of respiratory symptoms that result in additional therapy) with acute respiratory failure requiring admission to ICU and ventilatory support (invasive mechanical ventilation or non-invasive mechanical ventilation or high-flow nasal oxygen therapy with FiO2 ≥ 50%)
- Informed consent of patient, patient's immediate family/ or inclusion in an emergency situation
- Affiliation to a social security
Exclusion Criteria:
- The interval between admission to the hospital and admission to ICU more than 3 days
- Antibiotic therapy clearly needed for a suspected or documented extra-respiratory infection
- Congenital or acquired immunosuppression (congenital immune deficiency, high-grade hematologic malignancies, use of immunosuppressive drugs in the last 30 days including anti-cancer chemotherapy and antirejection medications, corticosteroid treatment ≥ 20 mg/d prednisone equivalent for at least 14 days, neutropenia, HIV with unknown or known CD4 <200 / µL in the past 6 months)
- Tracheotomy
- Bronchiectasis / cystic fibrosis
- Moribund patient (imminent death)
- Patient deprived of liberty and / or under legal protection measure
- Patient already included in MULTI-EXA
- Patient already included in a type 1 interventional study
- Ongoing pregnancy
Sites / Locations
- Intensive care department-Hospital TenonRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Other
Personalized strategy
Usual strategy
Personalized antibiotic treatment based on mPCR results, PCT (values and kinetics) and appearance of sputum. A broad panel respiratory mPCR FA-PPP is performed on a respiratory tract sample collected 12 hours after inclusion. After inclusion (D0), an algorithm of early antibiotic adaptation and discontinuation will be applied immediately and repeated every day until day 7. This algorithm of early antibiotic adaptation and discontinuation is based on a multimodal approach, using: The appearance of sputum (clinical approach); PCT values and kinetics (biological approach); Results of mPCR FA-PPP (microbiological approach).
Usual antibiotic treatment Left at the discretion of the physician as in usual practice